Login to Your Account


MORE THAN A B-CELL STORY

SAN DIEGO – Imbruvica, the BTK inhibitor that has racked up FDA approvals in B-cell cancers has impressed in a non-oncology indication chronic graft-vs.-host disease with phase II data showing an overall response rate of 67 percent.

more »


Our Habitat for All Things Science
Nobel Prize goes for autophagy research

"Basically, it's not easy to define what will serve humanity."

So said Yoshinori Ohsumi, honorary professor at the Tokyo Institute of Technology, after winning the 2012 Kyoto Prize in Life Sciences for his research.

The Nobel Assembly followed suit in recognizing the importance of Ohsumi's work, awarding him the 2016 Nobel Prize in Physiology or Medicine to "for his discoveries of mechanisms for autophagy."

READ MORE »

Opinion


Partners in Focus